Skip to main content

Main menu

  • Home
  • About
    • About CBM
    • Editorial Board
    • Announcement
  • Articles
    • Ahead of print
    • Current Issue
    • Archive
    • Collections
    • Cover Story
  • For Authors
    • Instructions for Authors
    • Resources
    • Submit a Manuscript
  • For Reviewers
    • Become a Reviewer
    • Instructions for Reviewers
    • Resources
    • Outstanding Reviewer
  • Subscription
  • Alerts
    • Email Alerts
    • RSS Feeds
    • Table of Contents
  • Contact us
  • Other Publications
    • cbm

User menu

  • My alerts

Search

  • Advanced search
Cancer Biology & Medicine
  • Other Publications
    • cbm
  • My alerts
Cancer Biology & Medicine

Advanced Search

 

  • Home
  • About
    • About CBM
    • Editorial Board
    • Announcement
  • Articles
    • Ahead of print
    • Current Issue
    • Archive
    • Collections
    • Cover Story
  • For Authors
    • Instructions for Authors
    • Resources
    • Submit a Manuscript
  • For Reviewers
    • Become a Reviewer
    • Instructions for Reviewers
    • Resources
    • Outstanding Reviewer
  • Subscription
  • Alerts
    • Email Alerts
    • RSS Feeds
    • Table of Contents
  • Contact us
  • Follow cbm on Twitter
  • Visit cbm on Facebook
Review ArticleReview

Fueling the engine and releasing the break: combinational therapy of cancer vaccines and immune checkpoint inhibitors

Jennifer Kleponis, Richard Skelton and Lei Zheng
Cancer Biology & Medicine September 2015, 12 (3) 201-208; DOI: https://doi.org/10.7497/j.issn.2095-3941.2015.0046
Jennifer Kleponis
1Department of Oncology, Department of Surgery, The Sidney Kimmel Comprehensive Cancer, The Skip Viragh Center for Pancreatic Cancer Research and Clinical Care, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard Skelton
2Masters of Health Science Program in Molecular Microbiology and Immunology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland 21287, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lei Zheng
1Department of Oncology, Department of Surgery, The Sidney Kimmel Comprehensive Cancer, The Skip Viragh Center for Pancreatic Cancer Research and Clinical Care, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: lzheng6{at}jhmi.edu
  • Article
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
Loading

Article Information

vol. 12 no. 3 201-208
DOI 
https://doi.org/10.7497/j.issn.2095-3941.2015.0046

Published By 
Cancer Biology & Medicine
History 
  • Received June 26, 2015
  • Accepted July 24, 2015
  • Published online September 1, 2015.

Copyright & Usage 
Copyright: © 2015, Cancer Biology & Medicine https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY) 4.0, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

Author Information

  1. Jennifer Kleponis1,
  2. Richard Skelton2 and
  3. Lei Zheng⇑1
  1. 1Department of Oncology, Department of Surgery, The Sidney Kimmel Comprehensive Cancer, The Skip Viragh Center for Pancreatic Cancer Research and Clinical Care, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
  2. 2Masters of Health Science Program in Molecular Microbiology and Immunology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland 21287, USA
  1. Correspondence to: Lei Zheng, E-mail: lzheng6{at}jhmi.edu
View Full Text

Cited By...

  • 85 Citations
  • Google Scholar
PreviousNext
Back to top

In this issue

Cancer Biology and Medicine: 12 (3)
Cancer Biology & Medicine
Vol. 12, Issue 3
1 Sep 2015
  • Table of Contents
  • Index by author
Print
Download PDF
Email Article

Thank you for your interest in spreading the word on Cancer Biology & Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Fueling the engine and releasing the break: combinational therapy of cancer vaccines and immune checkpoint inhibitors
(Your Name) has sent you a message from Cancer Biology & Medicine
(Your Name) thought you would like to see the Cancer Biology & Medicine web site.
Citation Tools
Fueling the engine and releasing the break: combinational therapy of cancer vaccines and immune checkpoint inhibitors
Jennifer Kleponis, Richard Skelton, Lei Zheng
Cancer Biology & Medicine Sep 2015, 12 (3) 201-208; DOI: 10.7497/j.issn.2095-3941.2015.0046

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Fueling the engine and releasing the break: combinational therapy of cancer vaccines and immune checkpoint inhibitors
Jennifer Kleponis, Richard Skelton, Lei Zheng
Cancer Biology & Medicine Sep 2015, 12 (3) 201-208; DOI: 10.7497/j.issn.2095-3941.2015.0046
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Immune checkpoints and their clinical inhibitors
    • Immune checkpoint inhibitors function on T cells
    • Vaccines: fueling the TME with T Cells
    • Fueling the engine and releasing the break: combination therapy
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • References
  • PDF

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • Spatial analysis of NOS2 and COX2 interaction with T-effector cells reveals immunosuppressive landscapes associated with poor outcome in ER- breast cancer patients
  • Global stability and parameter analysis reinforce therapeutic targets of PD-L1-PD-1 and MDSCs for glioblastoma
  • Prospective, randomized, double-blind phase 2B trial of the TLPO and TLPLDC vaccines to prevent recurrence of resected stage III/IV melanoma: a prespecified 36-month analysis
  • Expression of Three Clones of PD-L1 in Lung Cancer: A Single-center Experience
  • Google Scholar

More in this TOC Section

  • Harnessing the power of cancer-associated fibroblasts to revolutionize pancreatic cancer treatment
  • From residual risk to precision intervention: the evolving role of minimal residual disease in breast cancer management
  • Primary cilia in cancer: structures, functions, mechanisms, and therapeutic implications
Show more Review

Similar Articles

Keywords

  • cancer vaccine
  • immune checkpoint
  • immunotherapy
  • cytotoxic T-lymphocyte antigen-4 (CTLA-4)
  • programmed death-1 (PD-1)
  • programmed cell death ligand-1 (PD-L1)

Navigate

  • Home
  • Current Issue

More Information

  • About CBM
  • About CACA
  • About TMUCIH
  • Editorial Board
  • Subscription

For Authors

  • Instructions for authors
  • Journal Policies
  • Submit a Manuscript

Journal Services

  • Email Alerts
  • Facebook
  • RSS Feeds
  • Twitter

 

© 2025 Cancer Biology & Medicine

Powered by HighWire